X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cetuximab (2245) 2245
humans (2234) 2234
index medicus (2000) 2000
oncology (1931) 1931
colorectal cancer (1457) 1457
chemotherapy (1280) 1280
colorectal neoplasms - drug therapy (1206) 1206
female (1131) 1131
male (1101) 1101
cancer (1029) 1029
middle aged (993) 993
aged (942) 942
colorectal neoplasms - pathology (890) 890
1st-line treatment (833) 833
antineoplastic combined chemotherapy protocols - therapeutic use (757) 757
metastasis (751) 751
adult (726) 726
bevacizumab (712) 712
colorectal neoplasms - genetics (704) 704
mutation (665) 665
fluorouracil (646) 646
oxaliplatin (638) 638
antineoplastic agents - therapeutic use (631) 631
antibodies, monoclonal, humanized (613) 613
panitumumab (599) 599
care and treatment (581) 581
treatment outcome (580) 580
growth-factor receptor (577) 577
antibodies, monoclonal - therapeutic use (569) 569
irinotecan (549) 549
leucovorin (519) 519
cetuximab plus irinotecan (511) 511
kras (476) 476
receptor, epidermal growth factor - antagonists & inhibitors (470) 470
neoplasm metastasis (464) 464
aged, 80 and over (446) 446
camptothecin - analogs & derivatives (438) 438
survival (421) 421
ras proteins - genetics (416) 416
epidermal growth factor (409) 409
research (408) 408
disease-free survival (405) 405
egfr (403) 403
prognosis (395) 395
tumors (394) 394
antibodies, monoclonal - administration & dosage (389) 389
proto-oncogene proteins p21 (381) 381
therapy (380) 380
medicine & public health (374) 374
proto-oncogene proteins - genetics (367) 367
monoclonal antibodies (359) 359
metastatic colorectal-cancer (357) 357
drug therapy (355) 355
plus irinotecan (355) 355
phase-iii trial (348) 348
cancer therapies (333) 333
digestive system diseases (332) 332
analysis (330) 330
camptothecin - administration & dosage (330) 330
pharmacology & pharmacy (320) 320
colorectal neoplasms - mortality (314) 314
fluorouracil - administration & dosage (301) 301
neoplasms (293) 293
open-label (293) 293
metastatic colorectal cancer (291) 291
trial (291) 291
health aspects (289) 289
antineoplastic agents (284) 284
patients (280) 280
expression (274) 274
genetic aspects (274) 274
antineoplastic combined chemotherapy protocols - adverse effects (269) 269
hematology, oncology and palliative medicine (266) 266
colorectal carcinoma (262) 262
antimitotic agents (261) 261
retrospective studies (261) 261
antibodies, monoclonal - adverse effects (251) 251
receptor, epidermal growth factor - metabolism (251) 251
animals (248) 248
metastases (246) 246
combination (245) 245
clinical trials (238) 238
liver neoplasms - secondary (238) 238
organoplatinum compounds - administration & dosage (237) 237
surgery (234) 234
cancer research (228) 228
proto-oncogene proteins b-raf - genetics (228) 228
antineoplastic combined chemotherapy protocols - administration & dosage (223) 223
antineoplastic agents - adverse effects (215) 215
cell lung-cancer (213) 213
braf (209) 209
phase-ii trial (206) 206
capecitabine (198) 198
biomarkers (195) 195
survival rate (194) 194
epidermal growth factor receptor (190) 190
colorectal neoplasms - metabolism (189) 189
neoplasm staging (188) 188
ras mutations (188) 188
cancer patients (185) 185
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2850) 2850
French (28) 28
German (24) 24
Japanese (11) 11
Chinese (4) 4
Korean (2) 2
Arabic (1) 1
Italian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2004, Volume 351, Issue 4, pp. 337 - 345
... that was refractory to irinotecan therapy. The efficacy of the combination of antibody plus drug was clinically significant and was superior to that of the antibody alone... 
CELL LUNG-CANCER | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | MULTICENTER RANDOMIZED-TRIAL | PHASE-II TRIAL | TYROSINE KINASE | MONOCLONAL-ANTIBODY | ANTITUMOR-ACTIVITY | FLUOROURACIL-LEUCOVORIN | RESISTANT CHINESE-HAMSTER | Single-Blind Method | Adenocarcinoma - pathology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Topoisomerase I Inhibitors | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal, Humanized | Neoplasm Metastasis | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Agents - adverse effects | Exanthema - chemically induced | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Cetuximab | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease Progression | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Colorectal Neoplasms - pathology | Adenocarcinoma - mortality | Dosage and administration | Drug therapy, Combination | Research | Drug therapy | Colorectal cancer | Nuclear magnetic resonance--NMR | Epidermal growth factor
Journal Article
American Journal of Clinical Oncology: Cancer Clinical Trials, ISSN 0277-3732, 08/2016, Volume 39, Issue 4, pp. 340 - 345
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 749 - 759
...), irinotecan plus ciclosporin, and irinotecan plus panitumumab (IrPan) groups. From June 10, 2008, in response to new data... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | COLON-CANCER | 1ST-LINE TREATMENT | LEUCOVORIN | ONCOLOGY | BEVACIZUMAB | PROSPECTIVE MOLECULAR STRATIFICATION | CETUXIMAB PLUS IRINOTECAN | OXALIPLATIN | COMBINATION | CHEMOTHERAPY | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prospective Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Fluorouracil - therapeutic use | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Colorectal Neoplasms - enzymology | Camptothecin - therapeutic use | Drug Administration Schedule | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | United Kingdom | Chi-Square Distribution | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Drug Resistance, Neoplasm - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Clinical trials | Care and treatment | Antineoplastic agents | Colorectal cancer | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2015, Volume 33, Issue 7, pp. 692 - 700
Journal Article
International Journal of Cancer, ISSN 0020-7136, 02/2016, Volume 138, Issue 3, pp. 739 - 746
Journal Article
Annals of oncology, ISSN 0923-7534, 2015, Volume 26, Issue 1, pp. 132 - 140
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2008, Volume 26, Issue 14, pp. 2311 - 2319
Journal Article
Cancer, ISSN 0008-543X, 2013, Volume 119, Issue 24, pp. 4223 - 4230
Journal Article